by Gita Suneja, MD, MS, and Robert Miller, MD, MBA, FASTRO
We all aim to provide our patients with the best, most personalized care possible. Innovative research has identified a new frontier of cancer care: harnessing genomic and molecular data to develop treatment plans tailored to each unique patient with the potential to enhance treatment efficacy and limit toxicity. The use of biomarkers is growing within radiation oncology; however, more research is required to optimize biomarker use. To meet this need, the Radiation Oncology Institute (ROI) has selected “Biomarkers for Radiation Oncology” as the topic for its new request for proposals (RFP) to fund research grants aiming to improve patient outcomes in cancer treatment or improve the survivorship experience through the application of biomarkers.
The intent of the ROI’s new RFP is to solicit innovative ideas to leverage biomarkers for radiation oncology to enhance patient selection, to develop personalized treatment regimes, to quantify outcomes and manage toxicity. The grants, which will be announced next spring, will range from $50,000 up to $150,000 for projects with a larger scope. We invite all eligible applicants, including residents, to pursue this exciting new funding opportunity.
To apply, you must submit a Letter of Intent (LOI) through ProposalCentral by 5:00 p.m. Eastern time on November 16, 2020. The ROI Research Committee will review the LOIs and notify selected applicants to submit a full proposal in December. For examples of responsive projects, selection criteria and details on eligibility and how to apply, download the complete RFP.
As ASTRO’s research foundation, the ROI fills a special niche in funding for radiation oncology research, bringing together stakeholders from across the field to identify the highest priority topics for research that will heighten the critical role of radiation therapy in the treatment of cancer. The ROI is unique in that we develop a new RFP annually, allowing us to focus our funding resources on issues of immediate importance to the radiation oncology community. This year we were fortunate to have the added input from the ROI’s new Corporate Research Forum, a group of industry leaders that support the ROI; there was strong consensus among everyone involved in the RFP development process that biomarkers is a key area of research for radiation oncology right now.
We are eager to see all your creative research ideas to leverage biomarkers for radiation oncology with the potential to transform practice and improve outcomes for patients. Don’t miss your chance to apply for this year’s ROI funding opportunity by submitting your letter of intent by November 16.
Gita Suneja, MD, MS, is chair of the ROI Research Committee and vice-chair of CHEDI, and Robert Miller, MD, MBA, FASTRO, is vice-chair of the ROI Research Committee and editor-in-chief of Advances in Radiation Oncology.